GAMMA Investing
MAZE icon

GAMMA Investing’s Maze Therapeutics MAZE Stock Holding History

GAMMA Investing’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.29K Sell
158
-12
-7% -$333 ﹤0.01% 3710
2026
Q2 		$5.07K Sell
170
-182
-52% -$4.77K ﹤0.01% 3464
2026
Q1 		$10.5K Buy
352
+180
+105% +$7.94K ﹤0.01% 3051
2025
Q4 		$7.13K Buy
172
+13
+8% +$447 ﹤0.01% 3128
2025
Q3 		$4.12K Buy
159
+108
+212% +$1.82K ﹤0.01% 3248
2025
Q2 		$626 Buy
+51
New +$531 ﹤0.01% 3610

Other funds holding MAZE

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Mass General Brigham
Mass General Brigham Somerville, Massachusetts $456M AUM 27.51% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

GAMMA Investing's MAZE Position: Q3 2026 in Review

GAMMA Investing reduced its Maze Therapeutics (MAZE) stake by 7.1% in Q3 2026, selling an estimated $333 and leaving 158 shares worth $4.29K. The position accounts for ﹤0.01% of the portfolio, ranked #3710.

GAMMA Investing first reported a position in MAZE in Q2 2025 and has held it in 6 quarters since. The position peaked at $10.5K in Q1 2026. 47 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • GAMMA Investing held 158 shares of Maze Therapeutics worth $4.29K as of Q3 2026.
  • GAMMA Investing sold 12 Maze Therapeutics shares in Q3 2026, an estimated $333.
  • Maze Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3710 holding.
  • GAMMA Investing first reported a position in Maze Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • GAMMA Investing's Maze Therapeutics position peaked at $10.5K in Q1 2026.
  • 47 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.